Previous clinical studies from our group show that oral BH4 treatment in patients with coronary artery disease significantly elevates BH4 levels in blood, but this effect is significantly limited by systemic oxidation of exogenous BH4 to BH2, which lacks eNOS cofactor activity. Here, NOS3 is linked to coronary artery disorder.